Latest filing published 11 Feb 2025 for Marinus Pharmaceuticals, INC., €6,453. Read the official filing
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
This profile gathers the share dealings of Martha e. Manning in Marinus Pharmaceuticals, Inc., where the filings describe the role as board member. Between 4 February 2022 and 7 February 2025, the trades on record add up to 9 filings.
Every open-market trade on record is a sale: 3 sales worth €39k. Outside the open market, there are 5 share grants.
On 11 February 2025 came the latest disclosure, a transaction for €6,453 in Marinus Pharmaceuticals, Inc. Typically, a trade is published a median of 2 days after it takes place. Section 16 rules allow two business days to file each Form 4. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
9 of 9 declarations